BACKGROUND: HPV-infection, p16 positivity, and EGFR expression have been correlated with favorable responses of head and neck cancer patients treated with radiotherapy (RT) with or without chemotherapy. However, a possible correlation of HPV/p16 and EGFR status on the effect of RT in combination with cetuximab has not been sufficiently investigated. MATERIALS AND METHODS: We analyzed tumor samples for p16 and EGFR expression and correlated these variables with treatment outcome. Cox-proportional-hazard regression models were applied to compare the risk of death among patients stratified according to risk factors. Survival was estimated by the Kaplan-Meier method. Results were compared with an institutional historical control group treated without cetuximab and with published data. RESULTS: Expression of p16 was predominantly found in oropharyngeal squamous cell cancer patients (OPSCC; 36.6% positivity; 92% of all cases), while EGFR was expressed at high levels in all tumor subsites (82%). p16 expression was associated with improved overall survival in irradiated OPSCC patients (2-year overall survival of 80% in p16-positive vs. 33% overall survival in p16-negative patients). In a multivariable analysis covering all tumor sites, nodal stage (> N2a vs. ≤ N2a) and tumor site (OPSSC vs. non-OPSCC) had an impact on overall survival. CONCLUSION: Our results show that p16 positivity is associated with a favorable outcome in OPSCC patients treated with RT and cetuximab.
BACKGROUND:HPV-infection, p16 positivity, and EGFR expression have been correlated with favorable responses of head and neck cancerpatients treated with radiotherapy (RT) with or without chemotherapy. However, a possible correlation of HPV/p16 and EGFR status on the effect of RT in combination with cetuximab has not been sufficiently investigated. MATERIALS AND METHODS: We analyzed tumor samples for p16 and EGFR expression and correlated these variables with treatment outcome. Cox-proportional-hazard regression models were applied to compare the risk of death among patients stratified according to risk factors. Survival was estimated by the Kaplan-Meier method. Results were compared with an institutional historical control group treated without cetuximab and with published data. RESULTS: Expression of p16 was predominantly found in oropharyngeal squamous cell cancerpatients (OPSCC; 36.6% positivity; 92% of all cases), while EGFR was expressed at high levels in all tumor subsites (82%). p16 expression was associated with improved overall survival in irradiated OPSCC patients (2-year overall survival of 80% in p16-positive vs. 33% overall survival in p16-negative patients). In a multivariable analysis covering all tumor sites, nodal stage (> N2a vs. ≤ N2a) and tumor site (OPSSC vs. non-OPSCC) had an impact on overall survival. CONCLUSION: Our results show that p16 positivity is associated with a favorable outcome in OPSCC patients treated with RT and cetuximab.
Authors: Claudia Lill; Gabriela Kornek; Barbara Bachtiary; Edgar Selzer; Christian Schopper; Martina Mittlboeck; Martin Burian; Friedrich Wrba; Dietmar Thurnher Journal: Wien Klin Wochenschr Date: 2011-03-30 Impact factor: 1.704
Authors: Jean Bourhis; Michel Lapeyre; Jacques Tortochaux; Michel Rives; Mehdi Aghili; Sylvain Bourdin; François Lesaunier; Toufik Benassi; Claire Lemanski; Lionel Geoffrois; Antoine Lusinchi; Pierre Verrelle; Etienne Bardet; Morbize Julieron; Pierre Wibault; Monique Luboinski; Ellen Benhamou Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Richard C Jordan; Mark W Lingen; Bayardo Perez-Ordonez; Xin He; Robert Pickard; Michael Koluder; Bo Jiang; Paul Wakely; Weihong Xiao; Maura L Gillison Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: Felix Keil; Edgar Selzer; Andrea Berghold; Sabine Reinisch; Karin S Kapp; Alexander De Vries; Richard Greil; Barbara Bachtiary; Christoph Tinchon; Wolfgang Anderhuber; Martin Burian; Anne-Katrin Kasparek; Wolfgang Elsäßer; Herbert Kainz; Regina Riedl; Michael Kopp; Gabriela Kornek Journal: Eur J Cancer Date: 2012-09-14 Impact factor: 9.162
Authors: Bella Pajares; Jose M Trigo; Maria D Toledo; Martina Álvarez; Carlos González-Hermoso; Antonio Rueda; Jose A Medina; Vanessa de Luque; Jose M Jerez; Emilio Alba Journal: BMC Cancer Date: 2013-01-18 Impact factor: 4.430
Authors: Elisabeth Enzenhofer; Thomas Parzefall; Georg Haymerle; Sven Schneider; Lorenz Kadletz; Gregor Heiduschka; Johannes Pammer; Felicitas Oberndorfer; Fritz Wrba; Benjamin Loader; Matthäus Christoph Grasl; Christos Perisanidis; Boban M Erovic Journal: PLoS One Date: 2016-12-05 Impact factor: 3.240